Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

被引：0
|
作者：
Pierluigi Russo
Alessandro Capone
Andrea Paolillo
Francesco Macchia
Federica Ranzato
Gianfranco Costantino
Luca Degli Esposti
Luciano Caprino
机构：
[1] University of Rome “La Sapienza”,Department of Human Physiology and Pharmacology
[2] Economics and Outcome Research,Clicon S.r.l., Health
[3] University of Rome “La Sapienza”,Department of Neurological Sciences
[4] University of Padua,Neurologic Clinic I
[5] Ospedale Civile di Foggia,undefined
来源：
Clinical Drug Investigation | 2004年 / 24卷
关键词：
Multiple Sclerosis; Glatiramer Acetate; Oxybutynin; Tolterodine; Progressive Multiple Sclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 420
页数：11
相关论文
共 50 条
  • [31] Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    Calabrese, M.
    Bernardi, V.
    Atzori, M.
    Mattisi, I.
    Favaretto, A.
    Rinaldi, F.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 418 - 424
  • [32] Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Abdel-mannan, Omar A.
    Manchoon, Celeste
    Rossor, Thomas
    Southin, Justine-Clair
    Tur, Carmen
    Brownlee, Wallace
    Byrne, Susan
    Chitre, Manali
    Coles, Alasdair
    Forsyth, Rob
    Kneen, Rachel
    Mankad, Kshitij
    Ram, Dipak
    West, Siobhan
    Wright, Sukhvir
    Wassmer, Evangeline
    Lim, Ming
    Ciccarelli, Olga
    Hemingway, Cheryl
    Hacohen, Yael
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (04):
  • [33] Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis
    Manzano, A.
    Eskyte, I
    Ford, H. L.
    Pavitt, S. H.
    Potrata, B.
    Schmierer, K.
    Chataway, J.
    Webb, E. J. D.
    Meads, D.
    Pepper, G.
    Bekker, H. L.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [34] Treatment with disease-modifying drugs does not alter disability in relapsing-remitting multiple sclerosis
    Rolak, Loren A.
    Bejaoui, Khemissa
    Matti, Charmaine
    Foss, Dawn
    MULTIPLE SCLEROSIS, 2008, 14 : S176 - S176
  • [35] Disease-modifying effect of circuit class therapy in patients with relapsing-remitting multiple sclerosis
    Kolcava, J.
    Vlckova, E.
    Kocica, J.
    Sladeckova, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 395 - 396
  • [36] The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Marco Biolato
    Assunta Bianco
    Matteo Lucchini
    Antonio Gasbarrini
    Massimiliano Mirabella
    Antonio Grieco
    CNS Drugs, 2021, 35 : 861 - 880
  • [37] The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Biolato, Marco
    Bianco, Assunta
    Lucchini, Matteo
    Gasbarrini, Antonio
    Mirabella, Massimiliano
    Grieco, Antonio
    CNS DRUGS, 2021, 35 (08) : 861 - 880
  • [38] COST OFFSET ANALYSIS OF INTERFERON BETA DISEASE MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Beckerman, R.
    Locklear, J. C.
    Smith, N. J.
    Phillips, A. L.
    VALUE IN HEALTH, 2015, 18 (07) : A752 - A752
  • [39] Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis
    Lucchetta, Rosa C.
    Leonart, Leticia P.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 7 - 15
  • [40] The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
    Branger, Pierre
    Parienti, Jean-Jacques
    Sormani, Maria Pia
    Defer, Gilles
    PLOS ONE, 2016, 11 (03):
12345